Dr. Len Schleifer, CEO of Regeneron: Betting on Science and Saving a President

Regeneron Pharmaceuticals maintains its industry-leading position through a founder-led, long-term commitment to scientific innovation rather than short-term financial gains. Co-founders Dr. Leonard Schleifer and Dr. George Yancopoulos have steered the company for 38 years, prioritizing a diverse pipeline over single-molecule bets. This strategy enabled the development of blockbuster therapies like Eylea and Dupixent, alongside the rapid deployment of a life-saving monoclonal antibody cocktail during the COVID-19 pandemic. The company currently leverages its massive genetic database and advanced platforms—including siRNAs and gene editing—to address complex conditions like obesity, liver disease, and hereditary deafness. By avoiding the common industry trap of over-reliance on singular products or short-term analyst expectations, Regeneron sustains a robust, multi-faceted pipeline that continues to redefine treatment paradigms across multiple therapeutic areas.